Author
Primary ORCID profile (0000-0001-8247-3108 · 3 papers)Unclaimed ORCID profile · follow to get notified of new preprints
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
6 papers
Recent·Most cited
S. Bhattacharya, M. C. Jenkins, P. Keshavarz-Joud, A. R. Bourque, K. White, A. M. A. Barkane, A. V. Bryksin, C. Hernandez, M. Kopylov, M. G. Finn
This paper develops a vaccine strategy using immunologically orthogonal protein nanoparticles to focus antibody responses on a specific SARS-CoV-2 RBD epitope.
bioRxiv · Feb 24, 2024Immunology
S. N. Housley, L. Matyunina, S. Lee, O. Herrmann, J. Arboleda, J. F. McDonald, M. G. Finn
This paper develops a tumor-agnostic nanohydrogel (SANGs) platform for RNAi delivery, showing effective oncogene suppression and safety across species.
bioRxiv · Jan 22, 2024 · PreprintCancer Biology
V. Lensch, A. Gabba, R. Hincapie, S. H. Bhagchandani, A. Basak, M. M. Alam, D. J. Irvine, A. K. Shalek, J. A. Johnson, M. G. Finn, L. L. Kiessling
This study develops glycan-costumed virus-like particles that activate dendritic cells and induce type 1 anti-tumor immunity in a murine model.
bioRxiv · Jan 18, 2024 · PreprintBiochemistry
D. Wang, B. Zhou, T. Keppel, M. Solano, J. Baudys, J. Goldstein, M. G. Finn, X. Fan, A. P. Chapman, J. Bundy, A. R. Woolfitt, S. Osman, J. L. Pirkle, D. E. Wentworth, J. R. Barr
This study compares N-glycosylation profiles of SARS-CoV-2 spike proteins with D614G mutation and ancestral form using mass spectrometry, finding changes in glycan distribution and complexity.
bioRxiv · Jul 26, 2021Biochemistry
A. P. Chapman, X. Tang, J. R. Lee, A. Chida, K. Mercer, R. E. Wharton, M. H. Kainulainen, J. L. Harcourt, R. B. Martines, M. Schroeder, L. Zhao, A. Bryksin, B. Zhou, E. Bergeron, B. C. Bollweg, , J. M. Goldstein
This study develops and characterizes high-affinity mouse monoclonal antibodies against SARS-CoV-2, showing their neutralizing and diagnostic potential.
bioRxiv · Oct 13, 2020Immunology
E. L. Blanchard, D. Vanover, S. S. Bawage, P. M. Tiwari, L. Rotolo, J. Beyersdorf, H. E. Peck, N. C. Bruno, R. Hincapie, M. G. Finn, F. Michel, E. R. Lafontaine, R. J. Hogan, C. Zurla, P. J. Santangelo
This study uses mRNA-encoded Cas13a to target and reduce influenza and SARS-CoV-2 RNA in vitro and in a mouse model, showing potential for therapeutic applications.
bioRxiv · Apr 24, 2020 · PreprintBioengineering